CPHD

(redirected from Cepheid Inc)
AcronymDefinition
CPHDCertified Passive House Designer (course; North American Passive House Network)
CPHDCepheid Inc (stock symbol)
CPHDCombined Pituitary Hormone Deficiency
CPHDConference on Public Health and Disasters (Center for Public Health and Disasters; University of California, Los Angeles)
CPHDCentre for Policy and Human Development (Afghanistan)
CPHDChronic Pulmonary Heart Disease
CPHDCertified Philanthropic Development (National Association of Charitable Estate Counselors)
References in periodicals archive ?
Previously, Brown was a member of the boards of Cepheid Inc and Ventana Medical Systems Inc.
Danaher Corporation is merging with Cepheid Inc. for $4 billion, including indebtedness and net of acquired cash.
Cepheid Inc.'s (Sunnyvale CA) GeneXpert device correctly detected the bacterium within 90 minutes in about 98% of people with an active form of the lung disease, including a strain that evades the strongest antibiotic used to treat most patients, according to a study in the New England Journal of Medicine.
Key players in this market include Abbott Laboratories, Beckman Coulter Inc., Becton, Dickinson and Co, Biomerieux Sa, Cepheid Inc., Grifols, Hologic, Inc., Qiagen N.V., Roche Diagnostics and Siemens Healthcare.
Key companies operational in infectious diseases testing market are Becton Dickinson & Company, Cepheid Inc., Abbott Laboratories, BioMerieux, Hologic Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Affymetrix, Alere Inc., and DiaSorin.
Net income of USD12.9m was reported for the fiscal quarter ended 30 September 2012, including gain from the company's litigation settlement with Cepheid Inc.
Cepheid Inc. (Sunnyvale CA) received clearance for its diagnostic test to detect and differentiate two infection-causing bacteria in less than an hour.
Key players in this market include Affymetrix Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Biochain Institute Inc, Biomerieux Sa, Caliper Life Sciences In, Cepheid Inc, Cybrdi Inc, Emd Millipore, Fluidigm Corp, Gamida for Life Group, Illumina Inc, Imgenex, Life Technologies Corp and Origene Technologies Inc.
Companies profiled in this report are Roche Holdings AG, BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.
FDA ROUNDUP: Cepheid Inc. (Sunnyvale CA) received clearance to sell a test that detects a gene associated with resistance to a powerful antibiotic.
According to the paper, the biggest players in the hospital acquired disease testing market include Diatherix Laboratories Inc, Gen-Probe Inc (NASDAQ:GPRO), Qiagen GmbH (ETR:QIA), L Hoffman La Roche, part of Swiss Roche (VTX:ROG), Cepheid Inc (NASDAQ:CPHD), Life Technologies Corp (NASDAQ:LIFE), Meridian Biosciences, Cantel Medical Corp (NYSE:CMN) and Nordion Inc (TSE:NDN), among others.
The other vendors mentioned in the report are Illumina Inc., Becton Dickinson and Co., QIAGEN N.V., Affymetrix Inc., Johnson & Johnson, Thermo Fisher Scientific Inc., GE Healthcare, Life Technologies Corp., Luminex Corp., Cepheid Inc., bioMerieux SA, Allegro Diagnostics Corp., Fluidigm Corp., Nanosphere Inc., PerkinElmer Inc., Randox Laboratories Ltd., Oncolys BioPharma Inc., SomaLogic Inc., Radient Pharmaceuticals Corp., Quest Diagnostics Inc., Asuragen Inc., AVIVA Biosciences Corp., Veridex LLC, A.